SG11201507432XA - Antibody drug conjugate (adc) purification - Google Patents
Antibody drug conjugate (adc) purificationInfo
- Publication number
- SG11201507432XA SG11201507432XA SG11201507432XA SG11201507432XA SG11201507432XA SG 11201507432X A SG11201507432X A SG 11201507432XA SG 11201507432X A SG11201507432X A SG 11201507432XA SG 11201507432X A SG11201507432X A SG 11201507432XA SG 11201507432X A SG11201507432X A SG 11201507432XA
- Authority
- SG
- Singapore
- Prior art keywords
- adc
- purification
- drug conjugate
- antibody drug
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792834P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027062 WO2014152199A1 (en) | 2013-03-15 | 2014-03-14 | Antibody drug conjugate (adc) purification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507432XA true SG11201507432XA (en) | 2015-10-29 |
Family
ID=50686153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507432XA SG11201507432XA (en) | 2013-03-15 | 2014-03-14 | Antibody drug conjugate (adc) purification |
| SG10201800313UA SG10201800313UA (en) | 2013-03-15 | 2014-03-14 | Antibody drug conjugate (adc) purification |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201800313UA SG10201800313UA (en) | 2013-03-15 | 2014-03-14 | Antibody drug conjugate (adc) purification |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20140286968A1 (en) |
| EP (2) | EP4137160A1 (en) |
| JP (1) | JP2016519070A (en) |
| KR (1) | KR20150132864A (en) |
| CN (1) | CN105209076A (en) |
| AU (1) | AU2014240012A1 (en) |
| BR (1) | BR112015023520A2 (en) |
| CA (1) | CA2906022A1 (en) |
| HK (2) | HK1217643A1 (en) |
| IL (1) | IL241004A0 (en) |
| MX (1) | MX2015012562A (en) |
| NZ (1) | NZ630888A (en) |
| RU (1) | RU2015144186A (en) |
| SG (2) | SG11201507432XA (en) |
| TW (1) | TW201519904A (en) |
| WO (1) | WO2014152199A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| DK2968588T3 (en) * | 2013-03-15 | 2019-04-23 | Abbvie Deutschland | ANTI-EGFR ANTIBODY CONJUGATE PHARMACEUTICAL FORMULATIONS |
| CN110841074B (en) | 2014-03-21 | 2023-07-18 | 艾伯维公司 | anti-EGFR antibodies and antibody drug conjugates |
| CN106999606B (en) * | 2015-02-17 | 2020-06-19 | 上海美雅珂生物技术有限责任公司 | Antibody drug conjugates |
| WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
| MX2017014139A (en) | 2015-05-04 | 2018-07-06 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof. |
| EP3888689A1 (en) | 2016-06-08 | 2021-10-06 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| AU2017279554A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| CN109562190A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti-egfr antibodies drug conjugates |
| RU2764651C2 (en) | 2016-06-08 | 2022-01-19 | Эббви Инк. | Antibodies to b7-h3 and conjugates of antibody and drug |
| EP3468598A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015277A (en) | 2016-06-08 | 2019-09-06 | Abbvie Inc | Anti-b7-h3 antibodies and antibody drug conjugates. |
| MY196321A (en) * | 2016-08-16 | 2023-03-24 | Regeneron Pharma | Methods for Quantitating Individual Antibodies From a Mixture |
| TWI631958B (en) * | 2016-11-02 | 2018-08-11 | 財團法人生物技術開發中心 | Anti-tmcc3 immunoconjugates and uses thereof |
| JP7264482B2 (en) * | 2016-12-23 | 2023-04-25 | ブルーフィン バイオメディシン， インコーポレイテッド | Anti-DLL2 Antibodies and Antibody Drug Conjugates |
| CN107375941A (en) * | 2017-07-17 | 2017-11-24 | 中国药科大学 | A kind of anti-human DLL4 monoclonal antibodies and aplysiatoxin derivative MMAE conjugate |
| WO2019173911A1 (en) | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| US20220306685A1 (en) * | 2019-06-07 | 2022-09-29 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
| US20220289859A1 (en) | 2019-08-06 | 2022-09-15 | Glaxosmithkline Intellectual Property Development Limited | Biopharmacuetical Compositions and Related Methods |
| CN112604004B (en) * | 2019-09-19 | 2022-05-10 | 中国医学科学院医药生物技术研究所 | Anti-human EGFR antibody drug conjugate and preparation method and application thereof |
| AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
| KR20240040786A (en) | 2021-08-03 | 2024-03-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Biopharmaceutical compositions and stable isotope labeled peptide mapping methods |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| DE68921982T4 (en) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF. |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| JP3672306B2 (en) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | Heterodimeric receptor library using phagemids |
| ATE408012T1 (en) | 1991-12-02 | 2008-09-15 | Medical Res Council | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
| ATE243745T1 (en) | 1994-01-31 | 2003-07-15 | Univ Boston | LIBRARIES OF POLYCLONAL ANTIBODIES |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
| EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US20030027253A1 (en) * | 2000-11-28 | 2003-02-06 | Presnell Scott R. | Cytokine receptor zcytor19 |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| ES2544527T3 (en) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
| JP2006507322A (en) | 2002-11-14 | 2006-03-02 | シンタルガ・ビーブイ | Prodrugs constructed as multiple self-detaching release spacers |
| ES2605443T3 (en) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| EP1725586B1 (en) | 2004-03-02 | 2015-01-14 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| US7662936B2 (en) * | 2004-04-07 | 2010-02-16 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| DK3248613T3 (en) | 2005-07-18 | 2022-03-14 | Seagen Inc | BETA-GLUCURONIDE-MEDICINE-LINKER CONJUGATES |
| CA2617907A1 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| MX2011011669A (en) * | 2009-05-01 | 2011-11-18 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof. |
| US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| EP2841093A4 (en) * | 2012-04-27 | 2016-04-06 | Cytomx Therapeutics Inc | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
-
2014
- 2014-03-14 CN CN201480025357.3A patent/CN105209076A/en active Pending
- 2014-03-14 EP EP22179414.2A patent/EP4137160A1/en not_active Withdrawn
- 2014-03-14 SG SG11201507432XA patent/SG11201507432XA/en unknown
- 2014-03-14 BR BR112015023520A patent/BR112015023520A2/en not_active IP Right Cessation
- 2014-03-14 NZ NZ630888A patent/NZ630888A/en not_active IP Right Cessation
- 2014-03-14 EP EP14722865.4A patent/EP2968589A1/en not_active Withdrawn
- 2014-03-14 US US14/210,602 patent/US20140286968A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027062 patent/WO2014152199A1/en active Application Filing
- 2014-03-14 CA CA2906022A patent/CA2906022A1/en not_active Abandoned
- 2014-03-14 AU AU2014240012A patent/AU2014240012A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029906A patent/KR20150132864A/en not_active Application Discontinuation
- 2014-03-14 SG SG10201800313UA patent/SG10201800313UA/en unknown
- 2014-03-14 JP JP2016502325A patent/JP2016519070A/en active Pending
- 2014-03-14 MX MX2015012562A patent/MX2015012562A/en unknown
- 2014-03-14 RU RU2015144186A patent/RU2015144186A/en not_active Application Discontinuation
- 2014-03-14 TW TW103109819A patent/TW201519904A/en unknown
-
2015
- 2015-09-01 IL IL241004A patent/IL241004A0/en unknown
-
2016
- 2016-05-16 HK HK16105608.5A patent/HK1217643A1/en unknown
- 2016-06-21 HK HK16107159.4A patent/HK1219056A1/en unknown
-
2019
- 2019-02-11 US US16/273,034 patent/US20190262417A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1219056A1 (en) | 2017-03-24 |
| CN105209076A (en) | 2015-12-30 |
| IL241004A0 (en) | 2015-11-30 |
| RU2015144186A (en) | 2017-04-24 |
| WO2014152199A1 (en) | 2014-09-25 |
| US20140286968A1 (en) | 2014-09-25 |
| AU2014240012A1 (en) | 2015-09-24 |
| CA2906022A1 (en) | 2014-09-25 |
| SG10201800313UA (en) | 2018-02-27 |
| US20190262417A1 (en) | 2019-08-29 |
| KR20150132864A (en) | 2015-11-26 |
| JP2016519070A (en) | 2016-06-30 |
| NZ630888A (en) | 2017-06-30 |
| EP2968589A1 (en) | 2016-01-20 |
| RU2015144186A3 (en) | 2018-03-19 |
| HK1217643A1 (en) | 2017-01-20 |
| EP4137160A1 (en) | 2023-02-22 |
| BR112015023520A2 (en) | 2017-10-24 |
| TW201519904A (en) | 2015-06-01 |
| MX2015012562A (en) | 2016-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1219056A1 (en) | Antibody drug conjugate (adc) purification (adc) | |
| ZA201905426B (en) | Drug combinations | |
| HK1210477A1 (en) | Antibody drug conjugate | |
| IL241277A0 (en) | Antibody drug conjugates | |
| GB2529950B (en) | Patient support | |
| GB2532671B (en) | Patient support | |
| ZA201508487B (en) | Antibody drug conjugates | |
| EP3060578A4 (en) | Antibody purification | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| SG11201600666SA (en) | Medicament comprising anti-phospholipase d4 antibody | |
| ZA201506465B (en) | Pharmaceutical preparation | |
| GB201310496D0 (en) | Pharmaceutical combinations | |
| GB201301723D0 (en) | Pharmaceutical combinations |